Lepu Biopharma Co., Ltd. (HKG:2157)

Lepu Biopharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	472.71	401.29	426.02	669.4	155.17	402.87
Short-Term Investments	-	11.08	8.78	8.81	59.07	27.87
Trading Asset Securities	63.63	63.63	63.63	-	-	330.66
Cash & Short-Term Investments	536.34	475.99	498.43	678.2	214.24	761.4
Cash Growth	-8.51%	-4.50%	-26.51%	216.57%	-71.86%	297.77%
Accounts Receivable	49.75	45.82	37.8	3.04	-	-
Other Receivables	71.56	35.97	17.37	22.3	0.07	0.12
Receivables	121.31	81.79	55.17	25.34	0.07	0.12
Inventory	46.81	22.79	29.41	24.06	24.18	19.57
Prepaid Expenses	-	63.89	89.36	81.62	73.34	62.27
Other Current Assets	-	1.05	4.78	3.58	2.3	-
Total Current Assets	704.45	645.51	677.15	812.8	314.13	843.35
Property, Plant & Equipment	1,052	1,051	1,087	1,039	978.44	770.04
Long-Term Investments	108.43	114.07	126.69	122.39	137.97	160.29
Goodwill	-	52.64	52.64	52.64	52.64	52.64
Other Intangible Assets	462.57	350.29	369.93	398.18	422.45	445.29
Long-Term Deferred Charges	-	32.33	11.65	-	-	-
Other Long-Term Assets	34.04	34.82	59.01	104.1	176.43	152.01
Total Assets	2,362	2,281	2,384	2,529	2,082	2,424
Accounts Payable	226.21	236.14	207.61	166.13	158.82	42.45
Accrued Expenses	-	34.48	32.88	32.51	23.96	20.65
Short-Term Debt	-	-	-	329.63	40.41	-
Current Portion of Long-Term Debt	636.79	538.41	434.3	30.36	20	-
Current Portion of Leases	36.84	44.36	28.34	37.17	22.91	22.28
Current Income Taxes Payable	-	16.91	1	1.51	1.94	0.91
Current Unearned Revenue	0.7	0.91	-	-	4	2
Other Current Liabilities	211.27	172.31	195.43	246.49	277.02	293.94
Total Current Liabilities	1,112	1,044	899.56	843.79	549.06	382.22
Long-Term Debt	240.34	255.94	260	290.06	232.47	147.27
Long-Term Leases	3.85	11.46	24.18	3.09	19.48	33.53
Long-Term Unearned Revenue	17.84	18.02	12	12	12	12
Long-Term Deferred Tax Liabilities	37.69	37.69	37.69	37.69	37.69	37.69
Other Long-Term Liabilities	238.3	232.27	262.17	441.79	384.29	309.18
Total Liabilities	1,650	1,599	1,496	1,628	1,235	921.89
Common Stock	1,711	1,711	1,659	1,659	1,532	1,493
Additional Paid-In Capital	-	2,578	2,420	2,420	1,842	1,620
Retained Earnings	-2,723	-2,765	-2,354	-2,331	-1,642	-631.44
Comprehensive Income & Other	1,758	-820.49	-828.8	-847.04	-894.2	-1,008
Total Common Equity	745.26	702.83	896.91	900.76	836.71	1,474
Minority Interest	-33.47	-21.02	-8.21	-	10.37	28.21
Shareholders' Equity	711.8	681.8	888.7	900.76	847.08	1,502
Total Liabilities & Equity	2,362	2,281	2,384	2,529	2,082	2,424
Total Debt	917.81	850.16	746.82	690.3	335.26	203.08
Net Cash (Debt)	-381.47	-374.17	-248.4	-12.1	-121.03	558.32
Net Cash Per Share	-0.22	-0.22	-0.15	-0.01	-0.08	0.49
Filing Date Shares Outstanding	1,711	1,711	1,659	1,659	1,659	1,532
Total Common Shares Outstanding	1,711	1,711	1,659	1,659	1,532	1,532
Working Capital	-407.34	-398.01	-222.42	-30.99	-234.93	461.13
Book Value Per Share	0.44	0.41	0.54	0.54	0.55	0.96
Tangible Book Value	282.7	299.9	474.34	449.95	361.62	975.59
Tangible Book Value Per Share	0.17	0.18	0.29	0.27	0.24	0.64
Buildings	-	660.23	45.55	45.55	-	-
Machinery	-	378.64	365.38	246.16	195.06	175.87
Construction In Progress	-	22.38	628.15	661.64	633.35	386.98
Leasehold Improvements	-	118.91	106.03	105.71	102.42	89.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.